Type 2 Diabetes

AID technology outperformed CGM alone to reduce HbA1c, without increasing hypoglycemia, in adults with insulin-treated type 2 diabetes.

AstraZeneca announced eneboparatide normalized serum calcium with statistical significance at 24 weeks compared with placebo.

In this episode, hosts discuss the launch of the Control-IQ+ AID algorithm with Laurel Messer, PhD, RN of Tandem Diabetes Care.

Initiation of the MOMENTUM clinical trial will explore the prevalence of endogenous hypercortisolism in patients with resistant hypertension.

In this episode, hosts discuss the impact of recently launched direct, cash pay options for people using semaglutide and tirzepatide.

A study of 3 large US cohorts found a higher intake of butter was linked to greater mortality rates, while plant-based oil intake lowered total mortality.

The pivotal trial showed superior weight loss to placebo at 68 weeks but fell short of ≥25% weight loss initially expected by Novo Nordisk.

This February 2025 month in review covers key updates in endocrinology, including the end to the semaglutide shortage and new automated insulin delivery data.

The February 2025 cardiology review covers pipeline updates in lipid management, key regulatory acceptances and approvals, and shifting ASCVD trial endpoints.

In this episode, hosts discuss the implications of recent changes in GLP-1 RA availability as well as diabetes technology updates.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

In a recent Diabetes Dialogue segment, hosts discussed the efficacy and safety of advanced hybrid closed-loop therapy with the MiniMed 780G system.

In this Diabetes Dialogue segment, hosts discussed the strengths of trial diversity and HbA1c reductions with automated insulin delivery in type 2 diabetes.

Our top 5 headlines included a new approval for atopic dermatitis, expert consensus on anaphylaxis care, and the end of the semaglutide shortage.

The US supply of semaglutide and semaglutide 2.4 mg now meets or exceeds current and projected demand, ending the long-running shortages of these blockbuster drugs.

Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.

In this episode, hosts offer perspective on recent studies assessing insulin delivery systems in adults with type 2 diabetes.

On February 14, 2025, the FDA approved the first rapid-acting biosimilar insulin product called nsulin-aspart-szjj (Merilog).

CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from the AlloStem pilot study in T2D.

Drs. Levine and Sisti discuss the ethical challenges of GLP-1 drug allocation, exploring fairness, disparities, and policy solutions for obesity and diabetes treatment.

Completion of the trial was announced in a financial update from Novo Nordisk, who explained the trial missed its primary endpoint for uACR improvement.

In a Q&A, Kasia Lipska, MD, MHS, discusses the impact of type 2 diabetes on the immune system and findings from her recent research.

The January 2025 endocrinology month in review highlights the latest from the FDA, key drug price negotiations, and the latest updates to the obesity pipeline.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.